Odonate Therapeutics, Inc. (NASDAQ:ODT) Director Boxer Capital, Llc bought 300,000 shares of the stock in a transaction dated Monday, December 28th. The shares were acquired at an average cost of $17.06 per share, for a total transaction of $5,118,000.00. Following the completion of the acquisition, the director now directly owns 3,000 shares of the company’s stock, valued at approximately $51,180. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Boxer Capital, Llc also recently made the following trade(s):
- On Wednesday, December 30th, Boxer Capital, Llc acquired 100,000 shares of Odonate Therapeutics stock. The stock was purchased at an average cost of $17.46 per share, for a total transaction of $1,746,000.00.
NASDAQ ODT opened at $19.20 on Friday. The firm’s fifty day moving average price is $15.42 and its two-hundred day moving average price is $23.49. The stock has a market cap of $739.80 million, a PE ratio of -4.90 and a beta of 0.60. Odonate Therapeutics, Inc. has a fifty-two week low of $12.56 and a fifty-two week high of $46.50.
Large investors have recently modified their holdings of the company. Bank of Montreal Can acquired a new position in shares of Odonate Therapeutics during the second quarter worth $40,000. Great West Life Assurance Co. Can lifted its holdings in Odonate Therapeutics by 127.6% in the third quarter. Great West Life Assurance Co. Can now owns 1,543 shares of the company’s stock valued at $287,000 after buying an additional 865 shares during the period. BNP Paribas Arbitrage SA lifted its holdings in Odonate Therapeutics by 482.2% in the third quarter. BNP Paribas Arbitrage SA now owns 3,167 shares of the company’s stock valued at $43,000 after buying an additional 2,623 shares during the period. Jane Street Group LLC acquired a new position in Odonate Therapeutics in the second quarter valued at $257,000. Finally, American International Group Inc. increased its stake in Odonate Therapeutics by 40.5% in the second quarter. American International Group Inc. now owns 7,997 shares of the company’s stock valued at $339,000 after purchasing an additional 2,305 shares in the last quarter. Institutional investors own 74.69% of the company’s stock.
A number of research analysts recently issued reports on ODT shares. BidaskClub raised shares of Odonate Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, December 25th. Ci Capital reissued a “buy” rating and issued a $50.00 price objective on shares of Odonate Therapeutics in a research note on Wednesday, September 9th. Zacks Investment Research raised shares of Odonate Therapeutics from a “hold” rating to a “buy” rating and set a $17.00 target price on the stock in a research note on Thursday, December 3rd. Finally, Lifesci Capital reaffirmed an “outperform” rating on shares of Odonate Therapeutics in a research note on Wednesday, October 28th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $33.50.
Odonate Therapeutics Company Profile
Odonate Therapeutics, Inc, a pharmaceutical company, develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with locally advanced or metastatic breast cancer; and CONTESSA 2 and CONTESSA TRIO, which is in Phase II clinical study for central nervous system metastases and various cancer treatments.
Recommended Story: Why Invest in Dividend Kings
Receive News & Ratings for Odonate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Odonate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.